Clinical Trial Update: Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles [NA]

View source ↗

Summary

This clinical trial update evaluates the optimal dose of recombinant human chorionic gonadotropin (Ovidrel) for poor responders undergoing IVF/ICSI cycles. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infertility

Drugs mentioned

• Ovidrel (Choriogonadotropin alfa)

Snippet

Sponsor: Seoul National University Hospital | Conditions: in Vitro Fertilization, Poor Responder | NA | Status: UNKNOWN